<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369737">
  <stage>Registered</stage>
  <submitdate>7/12/2015</submitdate>
  <approvaldate>29/04/2016</approvaldate>
  <actrnumber>ACTRN12616000556448</actrnumber>
  <trial_identification>
    <studytitle>Protective effect of insulin against inhalation anesthesia induced apoptosis in laporoscopic cholecystectomy patients</studytitle>
    <scientifictitle>The Protective Effect of Insulin against Isoflurane or Sevoflurane Induced Hepatocellular Apoptosis in Laparoscopic Cholecystectomy Patients</scientifictitle>
    <utrn>Nil known</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>apoptosis in laporoscopic cholecystectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>80 patients undergoing laporoscopic cholecystectomy will be divide into 2 groups. After induction of general anesthesia with propofol 1mg kg-1 , fentanyl  2 microg kg-1 and atracurium 0.5 mg kg-1 then anesthesia will be maintained by: Arm 1 will receive isoflurane inhalational anesthetic by the dose 1.2% (1MAC) and Arm 2 sevoflurane inhalational anesthetic by the dose 2% (1MAC) after induction for maintenance of general anesthesia till the end of surgery. The type of surgery is laporoscopic cholecystectomy which lasts about one hour in our institute. Both inhalational anesthetic drugs will be monitored with infrared gas spectrophotometry to adjust the targeted end tidal concentration. Both arms will be subdivided into control subgroup which will receive 500 ml ringer acetate intravenous infusion 1 hour before surgery, and insulin subgroup which will receive  glucose insulin potassium (GIK) intravenous infusion to study its protective effect against apoptosis. GIK is composed  of 500 ml of 10% dextrose, 10 mEq of potassium and 10 IU of regular insulin. All fluids will be infused over 30 minutes and will be finished before starting the operation.  </interventions>
    <comparator>Patients undergoing laporoscopic cholecystectomy will be divided into 2 control groups. Arm 1 will recieve isoflurane inhalational anesthetic and Arm 2 sevoflurane inhalational anesthetic for maintenance of general anesthesia. Both groups will receive regular intravenous fluids solution (ringer acetate) with no drugs at a rate of 3ml kg-1h-1 and will be finished before starting the operation.  </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Apoptosis assessed by liver biopsy taken for immunohistochemical evaluation of hepatocyte apoptotic biomarkers (Bcl-xl, Akt, Fas, Fas-L, caspase-3,-7and-9) activity.</outcome>
      <timepoint>At the end of surgery before the umbilical port closure for all patients.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>apoptosis assessed by the following apoptotic biomarkers (Bcl-xl, Akt, Fas, FasL, annexinV, caspase-3,-7 and -9) in the blood.</outcome>
      <timepoint>3 ml of venous blood were collected two hours preoperatively (T0), at the end of surgery (T1) and one day after surgery (T24)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>liver function tests (ALT, AST, albumin, bilirubin (Total)), kidney function tests (blood urea and creatinine) </outcome>
      <timepoint>2 ml of venous blood were collected  2 hrs before surgery (T0) and 24 Hrs postoperatively (T24)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Elective laporscopic cholecystectomy.
Age: 25-55 years.
Gender: Both male and female.
 BMI: 20-30 kg/m2 (Normal weight).
ASA Class: I.</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy and lactation.
Fever or sepsis.
Addicts and drug abusers.
Acute cholecystitis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>14/02/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>2/02/2014</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize>80</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Giza</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Theodor Bilharz Research Institute</primarysponsorname>
    <primarysponsoraddress>El-Nile St., Warrak El-Hader, Imbaba Giza , Egypt P.O.BOX : 30 Imbaba</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Theodor Bilharz Research Institute</fundingname>
      <fundingaddress>El-Nile St., Warrak El-Hader, Imbaba Giza , Egypt P.O.BOX : 30 Imbaba</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Academy of scientific research and technology</sponsorname>
      <sponsoraddress>101 Kasr El Ainy St. Kasr El Ainy
Cairo 11516</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The hypothesis to be studied is that the commonly used inhaled anesthetics isoflurane and sevoflurane may induce apoptosis in liver and insulin can guard against their apoptotic effect. This study has two objectives:
The first one is to compare the apoptotic effect of isoflurane and sevoflurane on human hepatocytes and the second objective is to figure out the rule of insulin infusion as antiapoptoic agent in modulation of such effect evidenced by immunohistochemical study of liver biopsy and blood markers. Pre and postoperative liver and kidney function tests will be measured to help correlating the apoptotic changes with biochemical changes if present.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Review Board of Theodor Bilharz Research Institute (TBRI - IRB)</ethicname>
      <ethicaddress>Theodor Bilharz Research Institute El Nile St. Warrak ElHadar P.O. Box 30 Imbaba Giza, 12411 Egypt</ethicaddress>
      <ethicapprovaldate>11/02/2013</ethicapprovaldate>
      <hrec>FWA00010609</hrec>
      <ethicsubmitdate>2/01/2013</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/369737-Ethical committe approval.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Khalda Galal Radwan</name>
      <address>Theodor Bilharz Research Institute El Nile St. Warrak ElHadar P.O. Box 30 Imbaba Giza, 12411 Egypt</address>
      <phone>+201220411852</phone>
      <fax />
      <email>khalda.radwan31@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mohamed A. Maher</name>
      <address>Theodor Bilharz Research Institute El Nile St. Warrak ElHadar P.O. Box 30 Imbaba Giza, 12411 Egypt</address>
      <phone>+201005097625</phone>
      <fax />
      <email>d.mmaher@yahoo.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mohamed A.Maher</name>
      <address>Theodor Bilharz Research Institute El Nile St. Warrak ElHadar P.O. Box 30 Imbaba Giza, 12411 Egypt</address>
      <phone>+201005097625</phone>
      <fax />
      <email>d.mmaher@yahoo.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Moshira Sayed</name>
      <address>Theodor Bilharz Research Institute El Nile St. Warrak ElHadar P.O. Box 30 Imbaba Giza, 12411 Egypt</address>
      <phone>+201227206511</phone>
      <fax />
      <email>wayofangels@hotmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>